Literature DB >> 9934691

A recombinant measles virus expressing biologically active human interleukin-12.

M Singh, M A Billeter.   

Abstract

Suppression of cell-mediated immunity (CMI) is well-documented during and after measles. This immunosuppression is suggested to result from decreased production of interleukin-12 (IL-12), a key interleukin for CMI. In an attempt to clearly discern the role of IL-12 in measles-induced immunosuppression, a measles virus (MV) that expresses biologically active human IL-12 was generated. This was achieved by inserting the coding sequences of the two subunits (p35 and p40) of human IL-12 separated by an internal ribosome entry site in an additional transcription unit between the H and the L genes of MV. Although the IL-12-expressing MV grew slightly slower than the normal MV, it stably maintained the inserted sequences (3.2 kb) and uniformly expressed the foreign genes after 10 passages in cell culture. These findings suggest that MV is a well-suited vector for delivery of proteins of immunogenic and therapeutic importance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9934691     DOI: 10.1099/0022-1317-80-1-101

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  33 in total

1.  A recombinant measles vaccine virus expressing wild-type glycoproteins: consequences for viral spread and cell tropism.

Authors:  I C Johnston; V ter Meulen; J Schneider-Schaulies; S Schneider-Schaulies
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Rescue of mumps virus from cDNA.

Authors:  D K Clarke; M S Sidhu; J E Johnson; S A Udem
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector.

Authors:  A A Haller; T Miller; M Mitiku; K Coelingh
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Efficient replication of a paramyxovirus independent of full zippering of the fusion protein six-helix bundle domain.

Authors:  Melinda A Brindley; Philippe Plattet; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

5.  The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity.

Authors:  V von Messling; G Zimmer; G Herrler; L Haas; R Cattaneo
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

7.  Attenuated MuV-S79 as vector stably expressing foreign gene.

Authors:  Duo Zhou; Meng-Ying Zhu; Yi-Long Wang; Xiao-Qiang Hao; Dong-Ming Zhou; Rong-Xian Liu; Chu-Di Zhang; Chu-Fan Qu; Zheng-Yan Zhao
Journal:  World J Pediatr       Date:  2019-08-03       Impact factor: 2.764

8.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function.

Authors:  Patricia Devaux; Roberto Cattaneo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  A stabilized headless measles virus attachment protein stalk efficiently triggers membrane fusion.

Authors:  Melinda A Brindley; Rolf Suter; Isabel Schestak; Gabriella Kiss; Elizabeth R Wright; Richard K Plemper
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.